AR078494A1 - Formulaciones farmaceuticas en aerosol de formoterol y dipropionato de beclometasona - Google Patents
Formulaciones farmaceuticas en aerosol de formoterol y dipropionato de beclometasonaInfo
- Publication number
- AR078494A1 AR078494A1 ARP100103583A ARP100103583A AR078494A1 AR 078494 A1 AR078494 A1 AR 078494A1 AR P100103583 A ARP100103583 A AR P100103583A AR P100103583 A ARP100103583 A AR P100103583A AR 078494 A1 AR078494 A1 AR 078494A1
- Authority
- AR
- Argentina
- Prior art keywords
- formoterol
- formulation
- pressurized metered
- metered dose
- salt
- Prior art date
Links
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 title abstract 6
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 title abstract 5
- 229950000210 beclometasone dipropionate Drugs 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229960002848 formoterol Drugs 0.000 title abstract 2
- 239000000443 aerosol Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 229940071648 metered dose inhaler Drugs 0.000 abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 239000008249 pharmaceutical aerosol Substances 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229950000339 xinafoate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formulaciones farmacéuticas para su uso en la administracion de medicamentos por inhalacion. En particular, esta solicitud se relaciona con una formulacion farmacéutica que comprende dipropionato de beclometasona y una sal de formoterol para su uso en inhaladores presurizados de dosis medida (pMDI). Reivindicacion 1: Una formulacion farmacéutica en aerosol para su uso en inhaladores presurizados de dosis medida (pMDI) que comprende: (a) entre 0,001 y 0,05% p/p de una sal o un solvato de formoterol farmacéuticamente aceptable; (b) entre 0,05 y 0,16% p/v de dipropionato de beclometasona (BDP); (c) entre 2,0 y 4,8% p/p de etanol; (d) HFA 134a; caracterizada porque el unico propelente es HFA134a y la sal de formoterol se suspende en forma micronizada en la formulacion mientras que el corticoesteroide se disuelve totalmente. Reivindicacion 3: La formulacion de acuerdo con la reivindicacion 1 o 2, caracterizada porque la sal de formoterol se selecciona entre el grupo de fumarato, maleato, xinafoato y pamoato. Reivindicacion 8: El inhalador presurizado de dosis medida de acuerdo con la reivindicacion 7, caracterizado porque la dosis de la sal de formoterol es de 6 o 12 mg. Reivindicacion 9: El inhalador presurizado de dosis medida de acuerdo con la reivindicacion 7 u 8 caracterizado porque la dosis de dipropionato de beclometasona es de 50 o 100 mg.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172083 | 2009-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078494A1 true AR078494A1 (es) | 2011-11-09 |
Family
ID=42035850
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103583A AR078494A1 (es) | 2009-10-02 | 2010-10-01 | Formulaciones farmaceuticas en aerosol de formoterol y dipropionato de beclometasona |
| ARP200101303A AR123674A2 (es) | 2009-10-02 | 2020-05-07 | Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101303A AR123674A2 (es) | 2009-10-02 | 2020-05-07 | Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8420060B2 (es) |
| EP (2) | EP2482799B1 (es) |
| KR (1) | KR101778814B1 (es) |
| CN (2) | CN102548537B (es) |
| AR (2) | AR078494A1 (es) |
| BR (1) | BR112012007484A2 (es) |
| CA (1) | CA2776266C (es) |
| CY (2) | CY1115266T1 (es) |
| DK (2) | DK2727582T3 (es) |
| ES (2) | ES2487626T3 (es) |
| HK (2) | HK1199214A1 (es) |
| HR (2) | HRP20140818T1 (es) |
| HU (1) | HUE029159T2 (es) |
| JO (1) | JO3024B1 (es) |
| ME (1) | ME02398B (es) |
| PL (2) | PL2727582T3 (es) |
| PT (1) | PT2482799E (es) |
| RS (2) | RS53514B1 (es) |
| RU (1) | RU2650175C2 (es) |
| SI (2) | SI2482799T1 (es) |
| TW (1) | TWI449523B (es) |
| WO (1) | WO2011038872A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9119777B2 (en) * | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| FI3412277T3 (fi) * | 2012-01-25 | 2023-03-23 | Chiesi Farm Spa | Kortikosteroidia ja beeta-adrenergista ainetta käsittävä kuivajauheformulaatio annettavaksi inhalaatiolla |
| US11052202B2 (en) * | 2012-11-07 | 2021-07-06 | Chiesi Farmaceutici S.P.A. | Drug delivery device for the treatment of patients with respiratory diseases |
| CN112472689B (zh) | 2015-12-04 | 2023-01-17 | 墨西哥氟石股份公司 | 药物组合物 |
| CN112438966B (zh) * | 2019-08-30 | 2022-08-26 | 四川普锐特药业有限公司 | 一种医用定量吸入气雾剂 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5290539A (en) | 1990-12-21 | 1994-03-01 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
| WO1995002651A1 (en) | 1993-07-15 | 1995-01-26 | Minnesota Mining And Manufacturing Company | Seals for use in an aerosol delivery device |
| GB9612297D0 (en) * | 1996-06-11 | 1996-08-14 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
| US6423298B2 (en) * | 1998-06-18 | 2002-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
| SE9900833D0 (sv) * | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
| IT1317720B1 (it) | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| UA73986C2 (uk) * | 2000-05-22 | 2005-10-17 | К'Єзі Фармачеутічі С.П.А. | АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ |
| US6472563B1 (en) * | 2001-11-09 | 2002-10-29 | Sepracor Inc. | Formoterol tartrate process and polymorph |
| GB0205327D0 (en) * | 2002-03-06 | 2002-04-17 | Glaxo Group Ltd | compounds |
| GB0323685D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| EP1982709A1 (en) * | 2007-04-19 | 2008-10-22 | CHIESI FARMACEUTICI S.p.A. | Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma |
| RU2356537C2 (ru) * | 2007-07-25 | 2009-05-27 | Закрытое Акционерное Общество (ЗАО) "Пульмомед" | Фармацевтический состав дозированных аэрозолей, содержащий противоастматические лекарственные средства в виде суспензий, растворов, эмульсий, растворов и эмульсий |
-
2010
- 2010-09-27 EP EP10763317.4A patent/EP2482799B1/en active Active
- 2010-09-27 SI SI201030721T patent/SI2482799T1/sl unknown
- 2010-09-27 ES ES10763317.4T patent/ES2487626T3/es active Active
- 2010-09-27 BR BR112012007484A patent/BR112012007484A2/pt not_active Application Discontinuation
- 2010-09-27 ME MEP-2016-85A patent/ME02398B/me unknown
- 2010-09-27 PT PT107633174T patent/PT2482799E/pt unknown
- 2010-09-27 CN CN201080044596.5A patent/CN102548537B/zh active Active
- 2010-09-27 DK DK14153337.2T patent/DK2727582T3/en active
- 2010-09-27 RS RSP20140459 patent/RS53514B1/en unknown
- 2010-09-27 EP EP14153337.2A patent/EP2727582B1/en active Active
- 2010-09-27 WO PCT/EP2010/005879 patent/WO2011038872A1/en active Application Filing
- 2010-09-27 KR KR1020127008437A patent/KR101778814B1/ko active Active
- 2010-09-27 RU RU2012112454A patent/RU2650175C2/ru active
- 2010-09-27 PL PL14153337T patent/PL2727582T3/pl unknown
- 2010-09-27 RS RS20160274A patent/RS54721B1/en unknown
- 2010-09-27 SI SI201031156A patent/SI2727582T1/sl unknown
- 2010-09-27 HU HUE14153337A patent/HUE029159T2/hu unknown
- 2010-09-27 CN CN201410156323.XA patent/CN103919785B/zh active Active
- 2010-09-27 CA CA2776266A patent/CA2776266C/en active Active
- 2010-09-27 ES ES14153337.2T patent/ES2568913T3/es active Active
- 2010-09-27 PL PL10763317T patent/PL2482799T3/pl unknown
- 2010-09-27 DK DK10763317.4T patent/DK2482799T3/da active
- 2010-09-30 JO JOP/2010/0338A patent/JO3024B1/ar active
- 2010-10-01 AR ARP100103583A patent/AR078494A1/es not_active Application Discontinuation
- 2010-10-01 TW TW099133496A patent/TWI449523B/zh active
- 2010-10-04 US US12/897,117 patent/US8420060B2/en active Active
-
2012
- 2012-08-31 HK HK14112828.7A patent/HK1199214A1/xx unknown
- 2012-08-31 HK HK12108522.6A patent/HK1167817A1/xx unknown
-
2014
- 2014-07-10 CY CY20141100517T patent/CY1115266T1/el unknown
- 2014-09-01 HR HRP20140818AT patent/HRP20140818T1/hr unknown
-
2016
- 2016-04-26 CY CY20161100345T patent/CY1117596T1/el unknown
- 2016-06-08 HR HRP20160630TT patent/HRP20160630T1/hr unknown
-
2020
- 2020-05-07 AR ARP200101303A patent/AR123674A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR130239A2 (es) | Método para reducir la cantidad del producto de degradación dp3 durante la vida de estante de una composición farmacéutica en solución para aerosol y uso de una lata de aerosol asociada | |
| RS52940B (en) | PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS | |
| PE20160853A1 (es) | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) | |
| AR123674A2 (es) | Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona | |
| MX340924B (es) | Composiciones farmaceuticas. | |
| NZ600789A (en) | Aerosol formulation for copd | |
| CA2317999C (en) | Pharmaceutical formulation of fluticasone propionate | |
| AR038641A1 (es) | Formulacion superfina de formoterol | |
| NZ574658A (en) | Combination of azelastine and steroids such as fluticasone and mometasone for nasal and ocular use | |
| AR101593A2 (es) | Formulación superfina de formoterol | |
| FI3500241T3 (fi) | Yhdistelmähoito copd:lle | |
| KR20150096371A (ko) | 티오트로피움 및 히드로플루오로알칸을 포함하는 약학적 조성물 | |
| JP2019528316A5 (es) | ||
| AR040450A1 (es) | Formulacion superfina de salmeterol | |
| JP2017057223A5 (es) | ||
| JP2004529108A5 (es) | ||
| RU2012125965A (ru) | Аэрозольная препаративная форма для лечения по поводу хронического обструктивного легочного заболевания | |
| CL2012000947A1 (es) | Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis. | |
| EP3400214B1 (en) | Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives | |
| JP2013507430A5 (es) | ||
| PE20240807A1 (es) | Composiciones, metodos y sistemas para la administracion de farmacos en aerosol | |
| WO2004103339A3 (en) | Improved metered dose inhaler | |
| AR085443A1 (es) | Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero | |
| MX2007009836A (es) | Formulaciones en aerosol conteniendo una mezcla de propelentes. | |
| MXPA04001967A (es) | Formulaciones farmaceuticas en aerosol, contenido dipropionato de beclometasona. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |